Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Res Treat. 2012 Jun;44(2):74-84. doi: 10.4143/crt.2012.44.2.74. Epub 2012 Jun 30.

Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer.

Author information

1
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Abstract

Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.

KEYWORDS:

Combined modality therapy; Epidermal growth factor receptor; Individualized medicine; Lung neoplasms; Tyrosine kinase inhibitor

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Publishing M2Community Icon for PubMed Central
    Loading ...
    Support Center